Brind.

Cumberland Pharmaceuticals secured a new supply arrangement for its FDA-approved product, Vibativ.

2 reports, 1 independent Updated Aug 6

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Cumberland Pharmaceuticals secured a new supply arrangement for its FDA-approved product, Vibativ.

Who's involved

What this event is mainly about

FDA Cumberland Pharmaceuticals (United States)

Keep exploring

The entities involved

FDA
- Tarsus Pharmaceuticals is seeking FDA approval in the US and is listed on the Nasdaq stock exchange.05:07
- AtriCure, Inc. reported revenue via NASDAQ and received FDA 510(k) clearance for its device.02:45
Cumberland Pharmaceuticals (United States)
company in Nashville Tennessee United States

Nothing else this week.

Related events

Coverage

Newest first; wire copies grouped

Aug 6PR NewswireCumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date NASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, a
Aug 4PR NewswireCUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centers N